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Question: In patients investigated for suspected coronary heart disease, does a 
strategy involving cardiovascular magnetic resonance (CMR) result in less 
unnecessary angiography than a myocardial perfusion scintigraphy (MPS) strategy 
or a national guideline that included sending high-risk patients directly to 
angiography? 
Findings: In this clinical trial, both CMR and MPS strategies significantly 
reduced unnecessary angiography rates compared with national guidelines (7.5% 
for CMR, 7.1% for MPS, 28.8% for national guidelines); no statistically 
significant differences were seen between CMR and MPS strategies. There was no 
statistically significant difference in major cardiovascular event  rates at 12 
months between the 3 groups. 
Meaning: Noninvasive functional imaging strategies reduced unnecessary 
angiography compared with guidelines-directed care. 
Corresponding Author: John P. Greenwood, PhD, Leeds Institute of 
Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, 
Leeds Institute of Genetics, Health, and Therapeutics Building, Leeds, LS2 9JT, 
United Kingdom (j.greenwood@leeds.ac.uk). 
Group Information: The CE-MARC 2 investigators are listed in eTable 1 in 
Supplement 2. 
Importance  Among patients investigated for suspected coronary heart disease 
(CHD), rates of invasive angiography are considered too high, with limited data 
from randomized clinical trials evaluating strategies to reduce this. 
Objective  To test the hypothesis that in patients with suspected CHD, 
cardiovascular magnetic resonance (CMR)–guided care is superior to National 
Institute for Health and Care Excellence (NICE) guidelines–directed care and 
myocardial perfusion scintigraphy (MPS)–guided care, in reducing the occurrence 
of protocol-defined unnecessary angiography. 
Design, Setting, and Participants  Multicenter, 3-parallel group, randomized 
clinical trial using a pragmatic comparative effectiveness design. From 6 UK 
hospitals, 1202 symptomatic patients with suspected CHD and a CHD pretest 
likelihood of 10% to 90% were recruited. First randomization was November 23, 
2012, and the last 12-month follow-up was March 12, 2016. 
Interventions  Patients were randomly assigned (240:481:481) to management 
according to UK NICE guidelines or to guided care based on the results of CMR 
or MPS testing. 
Main Outcomes and Measures  The primary end point was protocol-defined 
unnecessary coronary angiography (defined by a normal fractional flow reserve 
[FFR] >0.8 or, when FFR was not possible, by quantitative coronary angiography 
[QCA] showing no percentage diameter stenosis ≥70% in 1 view or ≥50% in 2 
orthogonal views in all coronary vessels ≥2.5 mm diameter) within 12 months. 
Secondary end points included positive angiography, a major adverse 
cardiovascular event (MACE), and procedural complications. 
Results  Among 1202 symptomatic patients (mean age, 56.3 years [SD, 9.0]; 
women, 564 [46.9%] ; mean CHD pretest likelihood, 49.5% [SD, 23.8%]), 102 
(42.5%; 95% CI, 36.2%-49.0%) patients underwent invasive coronary 
angiography after 12 months in the NICE guidelines group; in the CMR group, 85 
(17.7%; 95% CI, 14.4%-21.4%) patients; and in the MPS group, 78 (16.2%; 95% 
CI, 13.0%-19.8%) patients. Study-defined unnecessary angiography occurred in 
69 patients in the NICE guidelines group (28.8%), 36 patients in the CMR group 
(7.5%), and 34 patients in the MPS group (7.1%). The adjusted odds ratio of 
unnecessary angiography for the CMR group vs the NICE guidelines group was 
0.21 (95% CI, 0.12-0.34, P < .001) and for the CMR group vs the MPS group was 
1.27 (95% CI, 0.79-2.03, P = .32). Positive angiography proportions were 29/240 
(12.1% (95% CI, 8.2%-16.9%)) for the NICE guidelines group, 47/481 (9.8% 
(95% CI, 7.3%-12.8%)) for the CMR group, and 42/481 (8.7% (95% CI, 6.4%-
11.6%)) for the MPS group. A MACE was reported at a minimum of 12 months in 
1.7% of patients in the NICE guidelines group; in the CMR group, 2.5%; and in 
the MPS group, 2.5%  (adjusted hazard ratios: CMR group vs NICE guidelines 
group, 1.37 [95% CI, 0.52-3.57]; CMR group vs MPS group, 0.95 [95% CI, 0.46-
1.95]). 
Conclusions and Relevance  In patients with suspected angina, investigation by 
CMR produced a lower probability of unnecessary angiography within 12 months 
than NICE guideline–directed care, with no statistically significant difference 
between CMR and MPS strategies. There were no statistically significant 
differences in MACE rates at 12 months after randomization. 
Trial Registration  Clinicaltrials.gov Identifier: NCT01664858. 
This randomized clinical trial investigates whether cardiovascular magnetic 
resonance–guided care is superior to National Institute for Health and Care 
Excellence guidelines–directed care and myocardial perfusion scintigraphy–
guided care in reducing the occurrence of unnecessary angiography among 
patients with suspected coronary heart disease. 
Introduction 
Coronary heart disease (CHD) is a leading cause of death and disability 
worldwide. Several investigations are available to diagnose CHD, risk-stratify 
patients, and determine the need for revascularization. Myocardial perfusion 
scintigraphy (MPS) by single-photon emission computed tomography is the most 
commonly used test worldwide for the assessment of myocardial ischemia, with 
robust evidence supporting its prognostic value. However, cardiovascular 
magnetic resonance (CMR) is increasingly recognized as having high diagnostic 
accuracy and prognostic value.1,2 
Despite the widespread availability and recommendations for noninvasive 
imaging in international guidelines,3-5 invasive coronary angiography is commonly 
used early in diagnostic pathways in patients with suspected CHD. Evidence from 
large populations presenting with chest pain has confirmed that the majority will 
not have significant obstructive coronary disease6,7; a large US study reported that 
approximately 60% of elective cardiac catheterizations found no obstructive 
CHD.8 Thus, avoiding unnecessary angiography should reduce patient risk and 
provide significant financial savings. 
Current guidelines for investigation of stable chest pain advocate 
management based on the pretest likelihood of CHD.3-5 However, pretest 
likelihood models can overestimate CHD risk, therefore paradoxically increasing 
the probability of invasive coronary angiography.9 To date, there are no large-scale 
comparative effectiveness trials of different functional imaging strategies 
recommended by current guidelines. 
The Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart 
Disease 2 (CE-MARC 2) trial was designed to test the hypothesis that in patients 
with suspected CHD, CMR-guided care is superior to national guidelines–directed 
care4 and MPS-guided care,10 in reducing the occurrence of unnecessary invasive 
angiography occurring within 12 months. 
Methods 
Trial Design 
CE-MARC 2 was a multicenter, 3-parallel group, randomized clinical trial. 
It used a pragmatic comparative effectiveness design11 to determine the efficacy 
and safety of 3 strategies (CMR-guided care, MPS-guided care [following 
American College of Cardiology Foundation and American Heart Association 
appropriate use criteria],10 and UK National Institute for Health and Care 
Excellence [NICE] guidelines [CG95]4) for investigating patients with suspected 
CHD. The study was conducted in accordance with the protocol (available with 
the statistical analysis plan and full text of this article in Supplement 1), which was 
approved by the UK National Research Ethics Service (12/YH/0404) and 
institutional review boards of the participating centers. Study conduct was in 
accordance with the Declaration of Helsinki; all patients provided written 
informed consent. 
Trial Population 
Patients with suspected angina pectoris were eligible if they were 30 years 
or older, had a CHD pretest likelihood of 10% to 90%,4,12 and suitable for 
revascularization. Exclusion criteria included nonanginal chest pain, a normal 
MPS or cardiac computed tomography (CCT) result within the previous 2 years, 
being clinically unstable, previous myocardial infarction, previous coronary 
revascularization, and contraindication to any study noninvasive imaging test 
(eTable 4 in Supplement 2).11 Self-reported race/ethnicity was collected using 
Office for National Statistics fixed categories 
(http://www.datadictionary.nhs.uk/data_dictionary/attributes/e/end/ethnic_categor
y_code_de.asp). 
Randomization 
Patients were assigned using minimization, incorporating a random element 
and 1:2:2 allocation ratio13 through an automated 24-hour secure-access telephone 
service by the Clinical Trials Unit. Allocation was to 1 of 5 equally sized groups 
(A:B:C:D:E, stratifying on center, age [30-64 years and ≥65 years], CHD pretest 
likelihood [10%-29%, 30%-60%, 61%-90%], and sex) following whether 
management was by NICE guidelines–directed care (NICE guidelines group; 
group A) CMR-guided care (CMR group; groups B or C) or MPS-guided care 
(MPS group; groups D or E). Patients randomized to the NICE guidelines group 
were scheduled for CCT for patients with a pretest likelihood of 10% to 29%, 
MPS for patients with a pretest likelihood of 30% to 60%, or sent directly to 
coronary angiography for patients with CHD pretest likelihoods of 61% to 90%. 
Diagnostic Testing 
All investigations were performed and interpreted by certified local 
physicians using protocols conforming to international standards.14-17 Quality 
assurance was undertaken centrally throughout the trial by blinded, independent, 
modality-specific imaging experts (eTable 3 in Supplement 2). Ten percent of 
scans for each modality at each recruiting center were centrally reviewed for 
image quality and report accuracy. Detailed protocols for each imaging modality 
and criteria for reporting a positive result have been published11; a positive scan 
for CMR, MPS, or CCT resulted in protocol-defined invasive coronary 
angiography and fractional flow reserve (FFR) measurement.11 FFR measurement 
(PressureWire, St Jude Medical) was performed in all coronary vessels of 2.5 mm 
diameter or more with a 40% to 90% stenosis.11 When FFR measurement was not 
possible for clinical or safety reasons, quantitative coronary angiography (QCA) 
was performed. All FFR and QCA results were analyzed at the Glasgow 
Angiographic Core Laboratory by a single, independent, blinded observer. 
Positive angiography was defined as any lesion with an FFR value of 0.8 or less, 
or, if FFR measurement was not performed, a percentage diameter stenosis of 70% 
or higher in 1 view or 50% or higher in 2 orthogonal views. 
End Points 
The primary end point was protocol-defined unnecessary coronary 
angiography occurring within 12 months, defined by a normal FFR value (or 
QCA) in all vessels 2.5 mm or more in diameter. By design, this included any 
unnecessary angiography occurring after a false-positive test result, patients with 
high CHD pretest likelihood sent directly to coronary angiography (NICE 
guidelines group only), and imaging results that were either inconclusive or 
negative but overruled by the responsible physician.11 Secondary end points 
included a composite of major adverse cardiovascular events (MACEs: 
cardiovascular death, myocardial infarction, unplanned coronary revascularization, 
and hospital admission for cardiovascular cause), and positive angiography rates 
(recommended by the independent data monitoring and ethics committee). 
Complications directly related to trial investigations resulting in prolonged 
hospital stay or specific treatment were prespecified as safety secondary end 
points. Quality-of-life outcomes and cost-effectiveness analyses will be reported 
subsequently. 
Trial Oversight 
An independent data monitoring and ethics committee and trial steering 
committee assessed study conduct, integrity, and safety every 6 months (eTable 2 
in Supplement 2). 
Statistical Analysis 
Allowing for 20% noncompletion, 1200 patients would provide the study 
with 99% power to detect a difference in unnecessary angiography between CMR-
guided care and NICE guidelines–directed care (using 2:1 allocation), and 94% 
power between CMR-guided and MPS-guided care based on projected 
unnecessary angiography proportions of 4.5% for the CMR group, 11.7% for the 
MPS group, and 30% for the NICE guidelines group (2-sided, 5% significance for 
continuity-corrected χ2 test).18 
Logistic regressions were used to model odds of an unnecessary angiogram 
for CMR-guided management vs both NICE- and MPS-guided management, 
including stratification factors (treating centers as fixed effects). Analyses used 
intention-to-treat populations and were repeated in per-protocol populations. 
Multiple imputation (by fully conditional specification) was used for missing 
baseline, test, and end point data to ensure all participants could be included in the 
analysis, and avoid treating unknown values as certainly known (eg, with mean 
imputation and no-event imputation).19 Ten fully imputed analysis data sets were 
generated because the proportion of patients with any missing data was less than 
10%, and primary end point analyses on each data set were combined to produce 
the overall intention-to-treat effect using Rubin rules. The proportion of patients in 
each group with a MACE at 12 months and absolute differences in MACE rates 
were calculated. Confidence intervals for proportions and their differences were 
calculated by exact methods. Time to first MACE was modeled using Cox 
proportional hazards regression, including stratification and other prespecified 
factors (hypertension, ethnicity, smoking, and diabetes) and illustrated using 
Kaplan-Meier estimates. CMR and MPS groups were combined into a single 
“functional imaging” group to compare unnecessary angiography vs NICE 
guidelines–directed care in the 61% to 90% and 10% to 29% CHD pretest 
likelihood subgroups. Subgroup analyses were undertaken by including interaction 
effects in regression models. Statistical tests were 2-sided and called significant at 
the 5% level. Analyses used SAS (SAS Institute), version 9.4, after all randomized 
patients had completed the 12-month follow-up; there were no interim analyses. 
Results 
Trial Population 
Between November 2012 and March 2015, 13 957 patients were screened 
of whom 2205 were eligible (Figure 1 lists reasons for noneligibility and 
nonconsent). From 6 UK centers (Leeds, Glasgow, Leicester, Bristol, Oxford, 
London [St Georges]),1202 patients (55% of eligible) were recruited and allocated 
to NICE guidelines–directed care (n = 240) or management by CMR (n = 481) or 
MPS (n = 481) (Figure 1). 
Baseline Characteristics 
The mean age of patients was 56.3 years (SD, 9.0), 638 patients (53%) 
were men, the mean body mass index (BMI; calculated as weight in kilograms 
divided by height in meters squared) was 29.1 (SD, 5.2), and 1107 patients (92%) 
were classified ethnically as white (Table 1). The study population had a 
substantial burden of cardiovascular risk factors: 150 patients (12.5%) had 
diabetes, 458 patients (38.1%) had hypertension, 702 patients (58.4%) were past 
or current tobacco users, 483 patients (40.2%) had dyslipidemia, and 651 patients 
(54.2%) had a family history of premature CHD. Patients had a median of 2 of 
these 5 risk factors. All patients were symptomatic, with 401 patients (33.4%) 
reporting typical chest pain and 801 patients (66.6%) reporting atypical chest pain 
as their primary symptom. The assessment of cardiac risk, calculated according to 
the 2013 atherosclerotic cardiovascular disease risk score from the American 
College of Cardiology Foundation and American Heart Association guidelines, 
showed that 441 of 923 patients (47.8%) had a 10-year risk of events of 7.5% or 
higher.20 The mean pretest likelihood of obstructive CHD according to the Duke 
score was 49.5% (SD, 23.8%).12 
Test Conduct 
Of 481 patients assigned to the CMR group, 435 patients (90.4%) had CMR 
as the initial test (median time from randomization, 20 days [interquartile range, 
13-34]), 5 patients (1.0%) had MPS, 5 patients (1.0%) went directly to 
angiography, and 23 patients (4.8%) had no test. Of 481 patients assigned to the 
MPS group, 446 patients (92.7%) had MPS as the initial test (median time from 
randomization, 28 days [interquartile range, 22-39]), 4 patients (0.8%) had CMR, 
5 patients (1.0%) went directly to angiography, and 21 patients (4.4%) had no test. 
Of 240 patients assigned to the NICE guidelines group, 56 patients (23.3%) had 
CCT (median time from randomization, 34 days [interquartile range, 14-44]), 86 
patients (35.8%) had MPS, 85 patients (35.4%) went directly to angiography, and 
11 patients (4.6%) had no test. The numbers of patients adherent to receiving both 
their initial randomized test and per-protocol compliance with their test result were 
200 patients (83.3%) in the NICE guidelines group, 414 patients (86.1%) in the 
CMR group, and 368 patients (76.5%) in the MPS group. 
Study sites reported their interpretation of the initial test as positive for 
CHD in 54 of 435 patients (12.4%) in the CMR group, in 81 of 446 patients 
(18.2%) in the MPS group, and in 19 of 142 patients (13.4%) in the NICE 
guidelines group. There was no difference in revascularization rates (Figure 1) 
between the 3 groups (P = .47). The rate of patients with incomplete data required 
for analysis of the primary end point was low: 18 of 240 patients (7.5%) in the 
NICE guidelines group, 50 of 481 patients (10.4%) in the CMR group, and 33 of 
481 patients (6.9%) in the MPS group. Of these, 11 of 240 patients (4.6%) in the 
NICE guidelines group, 23 of 481 patients (4.8%) in the CMR group, and 21 of 
481 patients (4.4%) in the MPS group were related to missing test results. 
Primary End Point 
Overall, 265 patients (22.0%) underwent at least 1 coronary angiogram (10 
patients underwent 2 angiograms) within 12 months of randomization: 102 of 240 
patients (42.5%) in the NICE guidelines group, 85 of 481 patients (17.7%) in the 
CMR group, and 78 of 481 patients (16.2%) in the MPS group. The primary end 
point of unnecessary angiography occurred in 69 patients (28.8%) in the NICE 
guidelines group, 36 patients (7.5%) in the CMR group, and 34 patients (7.1%) in 
the MPS group. Of these angiograms, 98 angiograms (70.5%)  had no visual 
stenosis and were not assessed further, 40 angiograms (28.8%) reached the 
conclusion by FFR measurement and 1 angiogram (0.7%) involved QCA only. 
The adjusted odds ratio of unnecessary angiography for the CMR group vs the 
NICE guidelines group was 0.21 (95% CI, 0.12-0.34; P < .001) and 1.27 (95% CI, 
0.79-2.03; P = .32) for the CMR group vs the MPS group. Table 2 shows 
individual components of the primary end point. For both comparisons, the 
primary analysis was repeated in the per-protocol population, with no effect on the 
trial results. Sensitivity analyses using random center effects or adjusting for 
further risk factors (hypertension, ethnicity, smoking status) or using the per-
protocol population did not change overall trial conclusions (eTable 5 in 
Supplement 2). Exploratory subgroup analyses showed consistent results across 
subgroups (Figure 2). 
Secondary End Points 
Positive angiography was observed in 29 patients (12.1% [95% CI, 8.2%-
16.9%]) in the NICE guidelines group, 47 patients (9.8% [95% CI, 7.3%-12.8%]) 
in the CMR group, and 42 patients (8.7% [95% CI, 6.4%-11.6%) in the MPS 
group (P = .36). During the minimum 1-year follow-up (median, 15.8 months 
[interquartile range, 12.1-24.2]), 36 patients (3.0%) had at least 1 MACE: NICE 
guidelines group, 6 patients (2.5%); CMR group, 15 patients (3.1%); MPS group, 
15 patients (3.1%) (Table 2). Annualized MACE rates were 1.6% for the NICE 
guidelines group, 2.0% for the CMR group, and 2.0% for the MPS group. 
Adjusted hazard ratios for MACE were 1.37 (95% CI, 0.52-3.57; P = .52) for the 
CMR group vs the NICE guidelines group and 0.95 (95% CI, 0.46-1.95; P = .88) 
for the CMR group vs the MPS group. Hard events (cardiovascular death and 
myocardial infarction) occurred in 3 patients (1.3%) in the NICE guidelines group, 
5 patients (1.0%) in the CMR group, and 4 patients (0.8%) in the MPS group (P = 
.93). Figure 3 shows the Kaplan-Meier cumulative incidence estimate of first 
MACE. In the study, five test-related medical complications were reported: CMR 
(1 case: mild urticarial reaction), MPS (0 cases), cardiac CT (1 case: vasovagal 
episode) and angiography (3 cases: ventricular tachycardia; pseudo-aneurysm & 
popliteal DVT; right coronary artery spasm & transient ST elevation). 
Functional Imaging Assessment 
Using functional imaging as a first-line strategy (CMR or MPS) in patients 
with a 61% to 90% (high, n=389) CHD pretest likelihood resulted in substantially 
reduced odds of unnecessary angiography compared with the NICE guidelines 
group; 29/307 (9.4%) vs 51/82 (62.2%), odds ratio (OR) 0.048 (95% CI, 0.02-
0.10), P < .001. Among those with less than 30% (low, n=330) CHD pretest 
likelihood, the odds of unnecessary angiography were also numerically lower by a 
functional imaging approach compared with anatomical (CCT) assessment; 13/269 
(4.8%) vs 7/61 (11.5%), odds ratio, 0.44 (95% CI, 0.17-1.17); P = .099). 
Discussion 
CE-MARC 2 was a multicenter, randomized clinical trial in a large 
community-based population of symptomatic patients undergoing assessment for 
suspected CHD, in whom further investigation was appropriate according to 
international guidelines. A CMR-guided strategy significantly reduced 
unnecessary angiography occurrence compared with NICE guidelines-guided care, 
but was not significantly different from an MPS-guided strategy (following US 
appropriate use criteria).10 Between the 3 strategies, there was no difference in 
short-term MACE rates or disease detection (positive angiography) rates. 
There is concern that coronary angiography is overused in the diagnostic 
pathway of suspected CHD, and that the majority of patients investigated will not 
have significant obstructive coronary disease.6,7 Avoiding unnecessary invasive 
angiography could have significant financial benefits, avoids exposing patients to 
unnecessary risk, and is also a strong patient desire.21 For this reason, we chose 
this as our patient-focused primary end point. 
Current international guidelines for investigation and management of 
suspected CHD all suggest risk stratification based on pretest likelihood 
estimation.12,22,23 The Duke score, used in NICE guidelines, is based upon the 
original Diamond Forrester model, but includes additional demographic factors to 
further stratify risk.12 These models, derived more than 3 decades ago, tend to 
overestimate CHD risk because patient demographics, risk factors, and treatment 
have changed considerably over time.24 In the CE-MARC 2 trial, the reduction in 
unnecessary angiography by a CMR or MPS strategy appears largely driven by the 
overestimation of disease probability from using the Duke score. Current NICE 
guidelines categorize a pretest likelihood of 60% to 90% as being at high-risk of 
CHD, and recommend direct referral for angiography. In the CE-MARC 2 trial, 
this explained the majority of patients in the NICE-guidelines group who got 
referred for angiography (82 of 102 patients; 80.4%), and the majority of 
unnecessary angiograms (59 of 69 patients; 85.5%). This was further emphasized 
by the preplanned, subanalysis of any functional imaging (CMR or MPS) in the 
60% to 90% (high risk) pretest likelihood population, which showed substantially 
reduced odds of unnecessary angiography in this combined subgroup compared 
with the NICE guideline group. 
Overall, rates of disease detection (positive angiography) were comparable 
for the 3 strategies, suggesting no penalty for using functional imaging as a 
gatekeeper for angiography, even in high-risk subgroups. Consistent with 
published studies, the CE-MARC 2 trial showed a low overall rate of MACE in a 
stable chest pain population, with no early difference between strategies. 
It remains a point of debate as to whether all of our protocol-defined 
unnecessary angiograms are truly clinically unnecessary; some would argue that 
negative tests are the “price to pay” for not missing important disease in others. 
This assumes a population perspective, and our trial primary end point was 
derived after close consultation with patient and public representatives: from an 
individual patient perspective, an angiogram that does not change their treatment 
or their clinical outcome is considered by patients to have been unnecessary. 
Certainly guidelines are clear that physicians do not need to undertake 
angiography to either diagnose angina or offer primary prevention and symptom 
control. 
To our knowledge, there have been no randomized clinical trials comparing 
the performance of current management guidelines and a broad functional imaging 
approach in terms of important clinical end points. Although cross-sectional 
imaging (CMR and CCT) has improved diagnostic ability, benefits in terms of 
health outcomes are harder to demonstrate, partly due to complexity of subsequent 
treatment effects. Functional vs anatomical assessment as a potential gatekeeper to 
the catheterization laboratory is a topic of ongoing debate.25,26 The Prospective 
Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial showed 
no improvement in clinical outcomes using CCT vs a variety of functional tests in 
patients investigated for suspected CHD; whereas the CCT strategy increased rates 
of cardiac catheterization (12.2% vs 8.1%, P = .02) and 90 day coronary 
revascularization (6.2% vs 3.2%, P < .001).25 This may be important following a 
recent observational study of 544 US centers showing higher rates of inappropriate 
percutaneous coronary intervention at sites performing the highest rates of 
angiography, suggesting anatomical assessment could predispose patients to 
unnecessary therapy.27 Although numbers are small, in the CE-MARC 2 trial an 
increased rate of unnecessary angiography was suggested in the low-risk subgroup 
of the NICE guidelines group, the majority of whom underwent CCT. 
Limitations 
The false-positive and false-negative rates are often quantities of interest in 
evaluating diagnostic methods. The CE-MARC 2 trial only angiographically 
verified a subset of patients, contingent on strategy findings, and so cannot provide 
accurate estimates. The original CE-MARC trial defined the false-positive and 
false-negative rates for CMR and MPS, and showed CMR-guided strategy as 
being superior to the MPS-guided strategy.1 In the current study, there was no 
statistical difference between the CMR and MPS strategies for reduction in 
unnecessary angiography, despite the finding from the CE-MARC trial. However, 
the CE-MARC trial was able to detect small differences due to its paired design 
(all patients underwent all tests), whereas the current study compared independent 
groups, which confers lower power. 
The study population was predominantly white northern European, 
therefore findings may not translate to other populations; geographic heterogeneity 
of CHD incidence is well known.23 At trial initiation, contemporary guidelines 
used the Duke score,3,4 with the NICE guidelines classifying high risk for CHD as 
60% to 90% pretest likelihood. It is now recognized that this may overestimate 
CHD risk, such that recent guidelines5 have adopted a recalibrated risk model.23 
The primary end point was objective (using FFR measurement), although 
performance was not clinically possible in all cases; blinded core laboratory 
analysis of QCA data avoided subjective visual angiography interpretation. 
Overall full adherence to the protocol was high, with some unavoidable variation 
due to individual clinical practice, which could have introduced bias (eg, abnormal 
imaging results not proceeding to angiography). To mitigate this, analysis was by 
intention-to-treat principles and the primary end point was purposely all inclusive 
(ie, false-positives, true-negatives when not believed by clinicians, and also test 
failures). The slightly different rates of incomplete data (not statistically 
significant) between study groups was not of concern, as the data completeness 
rate was high overall. Per-protocol and sensitivity analyses (eTable 5 in 
Supplement 2) did not alter the trial conclusions. Although clinically robust, a 
MACE is not a proxy for a missed diagnosis or treatment (eg, missed opportunity 
for revascularization by not having angiography [due to a false-negative result]). 
However, it remains debatable whether revascularization for stable angina has 
prognostic benefit over optimal medical therapy, which will be answered by the 
ongoing International Study of Comparative Health Effectiveness With Medical 
and Invasive Approaches (ISCHEMIA) trial.28 Finally, quality of life and cost-
effectiveness analyses will be important for understanding the patient-centered 
perspectives and payor/policy implications of these findings; these data are 
currently being collected/analyzed. 
Conclusions 
In patients with suspected angina, investigation by CMR produced a lower 
probability of unnecessary angiography within 12 months than NICE guideline–
directed care, with no statistically significant difference between CMR and MPS 
strategies. There were no statistically significant differences in MACE rates at 12 
months after randomization. 
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Figure 1. Flow of Patients Through the Study 
ACS indicates acute coronary syndrome; CABG, coronary artery bypass 
grafting; CCT, cardiac computed tomography; CMR, cardiovascular 
magnetic resonance; DSE, dobutamine stress echo; ETT, exercise 
treadmill test; MPS, myocardial perfusion scintigraphy; NICE, National 
Institute for Health and Care Excellence; PCI, percutaneous coronary 
intervention; PTL, pretest likelihood. 
aPatients may have received more than 1 test, in addition to or as an 
alternative to their strategy. 
Figure 2. Effect of Specific Patient Characteristics on Results for CMR-
Guided Care vs NICE Guidelines-Directed Care and MPS-Guided Care 
Among Patients With Suspected Coronary Heart Disease 
BMI indicates body mass index (calculated as weight in kilograms divided 
by height in meters squared); CMR, cardiovascular magnetic resonance; 
ITT, intention to treat; NICE, National Institute for Health and Care 
Excellence; MPS, myocardial perfusion scintigraphy. 
Figure 3. Time to First Major Adverse Cardiovascular Event After a 
Minimum of 12-Month Follow-Up From Randomization Among Patients 
With Suspected Coronary Heart Disease (Median, 16 Months) 
CMR indicates cardiovascular magnetic resonance; NICE, National 
Institute for Health and Care Excellence; MPS, myocardial perfusion 
scintigraphy.
Table 1. Baseline Characteristics of Participants With Suspected 
Coronary Heart Disease (CHD) by Study Group 
Characteristic Total Patients, 
No. (%) 
(N = 1202) 
Guided Care, No. (%) 
NICE 
(n = 240) 
CMR 
(n = 481) 
MPS 
(n = 481) 
Age, mean (SD), y 56.3 (9.03) 56.5 (9.21) 56.5 (9.10) 55.9 (8.87) 
Women 564 (46.9) 112 (46.7) 227 (47.2) 225 (46.8) 
Nonwhite ethnicity 95 (7.9) 19 (7.9) 38 (7.9) 38 (7.9) 
Cardiac risk factors     
  BMI, mean (SD) 29.1 (5.23) 29.0 (5.24) 29.2 (5.36) 29.1 (5.12) 
  Hypertension 458 (38.1) 99 (41.3) 177 (36.8) 182 (37.8) 
  Diabetes 150 (12.5) 24 (10.0) 53 (11.0) 73 (15.2) 
  Dyslipidemia 483 (40.2) 99 (41.3) 186 (38.7) 198 (41.2) 
  Current or past smoking 702 (58.4) 147 (61.3) 284 (59.0) 271 (56.3) 
  Family history of premature CHDa 651 (54.2) 140 (58.3) 252 (52.4) 259 (53.8) 
  Peripheral vascular disease 27 (2.2) 10 (4.2) 8 (1.7) 9 (1.9) 
  Cerebrovascular disease 42 (3.5) 8 (3.3) 17 (3.5) 17 (3.5) 
Nature of angina     
  Atypical 801 (66.6) 158 (65.8) 318 (66.1) 325 (67.6) 
  Typical 401 (33.4) 82 (34.2) 163 (33.9) 156 (32.4) 
Risk Burden 
Pretest likelihood, %     
  Mean (SD), %b 49.5 (23.78) 50.7 (23.28) 49.9 (24.25) 48.6 (23.57) 
  10-29c 314 (26.1) 61 (25.4) 128 (26.6) 125 (26.0) 
  30-60c 450 (37.4) 88 (36.7) 179 (37.2) 183 (38.0) 
  61-90c 438 (36.4) 91 (37.9) 174 (36.2) 173 (36.0) 
No. of risk factors per patient, mean (SD) 2.0 (1.13) 2.1 (1.05) 2.0 (1.18) 2.0 (1.11) 
10-y ASCVD risk >7.5%, No./total patients 
(%)d 
441/923 (47.8) 93/179 (52.0) 175/377 (46.4) 173/367 (47.1) 
Medications     
  Antiplatelet therapy 689 (57.3) 150 (62.5) 271 (56.3) 268 (55.7) 
  β Blocker 381 (31.7) 74 (30.8) 150 (31.2) 157 (32.6) 
  Statin or other lipid-lowering therapy 500 (41.6) 108 (45.0) 191 (39.7) 201 (41.8) 
  Angiotensin-converting enzyme inhibitor or 
angiotensin II receptor blocker 
303 (25.2) 66 (27.5) 115 (23.9) 122 (25.4) 
  Other antianginal medication 701 (58.3) 142 (59.2) 283 (58.8) 276 (57.4) 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index 
(calculated as weight in kilograms divided by height in meters squared); CMR, 
cardiovascular magnetic resonance; MPS, myocardial perfusion scintigraphy; NICE, 
National Institute for Health and Care Excellence. 
aFamily history of premature CHD defined as diagnosis of the disease in a male first-
degree relative before age 55 years or in a female first-degree relative age 65 years. 
bAccording to Pryor et al.12 
cCategories used to decide stratification in the NICE guidelines group. 
dAccording to edibility criteria of Goff et al.20
Table 2. Summary of Trial End Points for Patients With Suspected Coronary Heart Disease, by Each 
Guided Care Groupa 
 Total 
Patients 
(N = 1202) 
Guided Care Absolute Differences, % (95% CI) 
NICE 
Guidelines  
(n = 240) 
CMR 
(n = 481) 
MPS 
(n = 481) 
CMR vs NICE CMR vs MPS 
Primary End Point 
Unnecessary invasive 
angiography, No. (%) 
139 (11.6) 69 (28.8) 36 (7.5) 34 (7.1) −21.3  
(−28.7 to −13.6) 
0.4  
(−6.0 to 6.8) 
Components of the 
primary end point 
      
False-positive noninvasive 
test 
35 5 18 12   
Direct to angiography (by 
strategy) 
59 59     
Negative test, not per-
protocol 
41 5 15 21   
Inconclusive test/result 4 - 3 1   
Secondary End Points 
Positive angiography 
occurrence, No. (%) 
118 (9.8) 29 (12.1) 47 (9.8) 42 (8.7) −2.3  
(−10.0 to 5.4) 
1.0  
(−5.4 to 7.5) 
False-positive noninvasive 
test 
73 4 38 31   
Direct to angiography (by 
strategy) 
23 23     
Negative noninvasive test, 
not per-protocol 
9 1 2 6   
Inconclusive noninvasive 
test/result 
2  2    
Acute/urgent angiography 9 1 4 4   
indication 
Angiography as alternative 
initial investigation 
2 - 1 1   
Major adverse 
cardiovascular events, No. 
(No. of patients) 
44 (36) 7 (6) 20 (15) 17 (15) 1.0  
(−6.7 to 8.8) 
0.0  
(−6.4 to 6.4) 
  Cardiovascular death 5 1b 1 3   
  Myocardial infarction 9 2 5 2   
  Revascularization       
    Unplanned PCI 12 2 6 4   
    Unplanned CABG 1  1    
  Arrhythmia 9 2 4 3   
  Heart failure 4   4   
  Stroke/TIA 4  3 1   
Abbreviations: CABG, coronary artery bypass graft; CMR, cardiovascular magnetic resonance; MACE, major adverse cardiovascular 
events; MPS, myocardial perfusion scintigraphy; NICE, National Institute for Health and Care Excellence; PCI, percutaneous 
coronary intervention; TIA, transient ischemic attack. 
bThis event occurred 2 days after the 3-year cutoff, so is excluded from summaries of absolute MACE rates at 3 years. All other events 
occurred within 3 years of randomization. Three-year MACE rates include all participants (median follow-up, 16 months). 
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